Low molecular weight heparin-modified isoliquiritigenin-loaded solid lipid nanoparticle (LMWH-ISL-SLN) was developed for injective application. The morphological observation, particle diameter and zeta potential of LMWH-ISL-SLN were characterized using transmission electron microscopy (TEM) and a Malvern Zetasizer. Its entrapment efficiency (EE) and drug loading (DL) were determined by ultracen...

objective: to determine the incidence of deep vein thrombosis (dvt) in patients undergoing spinal surgeries receiving prophylactic doses of deltaparin in a single center in central iran. method: this cross-sectional study was conducted in shariatee hospital of isfahan during a 12-month period. we included all the patients undergoing elective spinal surgeries in our center during the study perio...

Low molecular weight heparin-modified isoliquiritigenin-loaded solid lipid nanoparticle (LMWH-ISL-SLN) was developed for injective application. The morphological observation, particle diameter and zeta potential of LMWH-ISL-SLN were characterized using transmission electron microscopy (TEM) and a Malvern Zetasizer. Its entrapment efficiency (EE) and drug loading (DL) were determined by ultracen...

low molecular weight heparin-modified isoliquiritigenin-loaded solid lipid nanoparticle (lmwh-isl-sln) was developed for injective application. the morphological observation, particle diameter and zeta potential of lmwh-isl-sln were characterized using transmission electron microscopy (tem) and a malvern zetasizer. its entrapment efficiency (ee) and drug loading (dl) were determined by ultracen...

Heparin-İnduced Thrombocytopenia (HIT) is a life-threatening complication that occurs in small percentage of exposed patients (e.g. unfractionated heparin, Low Molecular Weight Heparin [LMWH]) regardless dose and treatment management.

methods this randomized, crossover study with parallel design was conducted in 45 patients who required maintenance hemodialysis due to end-stage renal failure. four patients with known bleeding disorders, receiving anticoagulant drugs and receiving drugs which could affect heparin activity were excluded. all patients were randomly assigned to receive either enoxaparin sodium (0.7 mg/kg) or sta...

Low-molecular-weight heparin (LMWH) are most importantly used in the clinical practice for cardio vascular diseases from 1990. The LMWH was a sulfated polysaccharide obtained animal sources and some natural especially marine sources. actual anticoagulant has molecular weight about 25000 Daltons which have bleeding as side effect cardiovascular diseases. prepared by enzymatic or chemical hydroly...

Heparin and low-molecular-weight heparin (LMWH) are commonly monitored by determination of activated clotting times or chromogenic assays. Despite their wide use, these assays determine the biological activity and not the concentration of the anticoagulants. They may be inaccurate in some circumstances such as certain disease states. In addition, there is a significant interest in alternative t...